Literature DB >> 23907017

Cholesterol induces cardiac hypertrophy by activating the AKT pathway.

Hyunjung Lee1, Young Sook Yoo, Daekee Lee, Eun Joo Song.   

Abstract

Cardiac hypertrophy leads to decompensated heart function, predisposition to heart failure, and sudden death due to physiological and pathological stimuli. Although high cholesterol is considered a principal risk factor for atherosclerosis and heart disease, it has not been shown whether cholesterol itself is sufficient to cause cardiac hypertrophy. In this study, we investigated whether cholesterol induces cardiac hypertrophy, and identified cellular mechanisms underlying hypertrophic responses using H9c2 cells as a model system. Here we show that cholesterol loading significantly increased the cellular surface area and upregulated hypertrophy marker gene, β-myosin-heavy chain (β-MHC). Cholesterol loading alone activated the extracellular signal-regulated kinase (ERK)/mitogen activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. Conversely, cholesterol induced hypertrophic characteristic features such as increase in cellular surface area, and the expression of β-MHC mRNA is markedly inhibited by LY294002, a PI3K kinase inhibitor. These results suggest that cholesterol may play a key role in the development of cardiac hypertrophy through the activation of the PI3K/AKT pathway activation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AKT; Cardiac hypertrophy; Cholesterol; ERK; G-protein-coupled receptor; GPCR; GSK3β; H9c2 cells; IGF; MAPK; PI3K; extracellular signal-regulated kinase; insulin growth factor; mTOR; mammalian target of rapamycin; mitogen-activated protein kinase; phosphatidylinositol-3-kinase; phospho-glycogen synthase kinase-3β

Mesh:

Substances:

Year:  2013        PMID: 23907017     DOI: 10.1016/j.jsbmb.2013.07.008

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

1.  Triggering the succinate receptor GPR91 enhances pressure overload-induced right ventricular hypertrophy.

Authors:  Lei Yang; Di Yu; Huan-Huan Fan; Yu Feng; Liang Hu; Wei-Yan Zhang; Kai Zhou; Xu-Ming Mo
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Resistin-induced cardiomyocyte hypertrophy is inhibited by apelin through the inactivation of extracellular signal-regulated kinase signaling pathway in H9c2 embryonic rat cardiomyocytes.

Authors:  Jian-Wei Luo; Xian Zheng; Guan-Chang Cheng; Qun-Hui Ye; Yong-Zhi Deng; Lin Wu
Journal:  Biomed Rep       Date:  2016-09-02

3.  Management of Hypercholesterolemia Through Dietary ß-glucans-Insights From a Zebrafish Model.

Authors:  Adnan Hussain Gora; Saima Rehman; Viswanath Kiron; Jorge Dias; Jorge M O Fernandes; Pål Asgeir Olsvik; Prabhugouda Siriyappagouder; Ioannis Vatsos; Ulrike Schmid-Staiger; Konstantin Frick; Miguel Cardoso
Journal:  Front Nutr       Date:  2022-01-12

4.  Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells.

Authors:  Hyunjung Lee; Jinyoung Park; Eunice EunKyeong Kim; Young Sook Yoo; Eun Joo Song
Journal:  BMB Rep       Date:  2016-05       Impact factor: 4.778

5.  Development of a Predictive Model to Induce Atherogenesis and Hepato-Renal Impairment in Female Rats.

Authors:  Lucas Pires Guarnier; Paulo Vitor Moreira Romão; Rhanany Alan Calloi Palozi; Aniely Oliveira Silva; Bethânia Rosa Lorençone; Aline Aparecida Macedo Marques; Ariany Carvalho Dos Santos; Roosevelt Isaias Carvalho Souza; Karine Delgado Souza; Emerson Luiz Botelho Lourenço; Arquimedes Gasparotto Junior
Journal:  Biomolecules       Date:  2019-10-29

6.  Epigallocatechin gallate (EGCG) attenuates myocardial hypertrophy and fibrosis induced by transverse aortic constriction via inhibiting the Akt/mTOR pathway.

Authors:  Yue Cui; Yongqiang Wang; Gang Liu
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.